SCHEMBL15979735

SCHEMBL15979735

COc1ccc(C(=O)CCC(=O)c2ccc(C)c(C)c2)cc1C

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 3/20 0.62
WNT3A P56704 3/20 0.62
TAS1R3 Q7RTX0 5/20 0.50
TAS1R1 Q7RTX1 5/20 0.50
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
PAX8 Q06710 1/20 0.48
TSHR P16473 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
THRA P10827 1/20 0.46
THRB P10828 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5495178 0.89 CTNNB1 (0.60) CTNNB1WNT3ATAS1R3TAS1R1PAX8
SCHEMBL6339402 0.87 CTNNB1 (0.58) CTNNB1WNT3ATAS1R3TAS1R1PAX8
SCHEMBL15979737 0.85 CTNNB1 (0.61) CTNNB1WNT3APAX8TSHRMAPK1
SCHEMBL15979670 0.84 CTNNB1 (0.56) CTNNB1WNT3AMAPTLMNAGAA
SCHEMBL6085421 0.84 CTNNB1 (0.56) CTNNB1WNT3ATAS1R3TAS1R1MAPT
SCHEMBL9914237 0.84 CYP1A2 (0.63) TAS1R3TAS1R1MAPTLMNAGAA
SCHEMBL15980084 0.83 LMNA (0.60) CTNNB1WNT3AMAPTLMNAGAA
SCHEMBL15980081 0.83 CTNNB1 (0.63) CTNNB1WNT3AL3MBTL1
SCHEMBL3948073 0.83 MEN1 (0.60) CTNNB1WNT3ATAS1R3TAS1R1MAPT
SCHEMBL27660341 0.83 CTNNB1 (0.53) CTNNB1WNT3ATAS1R3TAS1R1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-9951053-B2 γ-diketones as Wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2018-04-24 US disclosed
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS MED-PATHWAYS II LIMITED (VG) 2017-09-14 US disclosed
US-9533976-B2 γ-diketones as WNT/β-catenin signaling pathway activators SAMUMED, LLC (US) 2017-01-03 US disclosed
US-20140243349-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS VENTURE FUND VI PTE. LTD. (SG) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885TAS1R3 4142/4885
US-20140243349-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885TAS1R3 4142/4885
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 CTNNB1 5/4885WNT3A 4/4885TAS1R3 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.